Reference - Detail
| RRC ID | 6505 |
|---|---|
| Author | Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, Nakatsura T, Nishimura Y, Senju S. |
| Title | Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. |
| Journal | Cancer Sci |
| Abstract |
The close cooperation of both innate and acquired immunity is essential for the induction of truly effective antitumor immunity. We tested a strategy to enhance the cross-talk between NKT cells and conventional antigen-specific T cells with the use of alpha GalCer-loaded dendritic cells genetically engineered to express antigen plus chemokine, attracting both conventional T cells and NKT cells. DC genetically engineered to express a model antigen, OVA, along with SLC/CCL21 or monokine induced by IFN-gamma/CXCL9, had been generated using a method based on in vitro differentiation of DC from mouse ES cells. The ES-DC were loaded with alpha-GalCer and transferred to mice bearing MO4, an OVA-expressing melanoma, and their capacity to evoke antitumor immunity was evaluated. In vivo transfer of either OVA-expressing ES-DC, stimulating OVA-reactive T cells, or alpha-GalCer-loaded non-transfectant ES-DC, stimulating NKT cells, elicited a significant but limited degree of protection against the i.p. disseminated MO4. A more potent antitumor effect was observed when alpha-GalCer was loaded to ES-DC expressing OVA before in vivo transfer, and the effect was abrogated by the administration of anti-CD8, anti-NK1.1 or anti-asialo GM1 antibody. alpha-GalCer-loaded double transfectant ES-DC expressing SLC along with OVA induced the most potent antitumor immunity. Thus, alpha-GalCer-loaded ES-DC expressing tumor-associated antigen along with SLC can stimulate multiple subsets of effector cells to induce a potent therapeutic effect against peritoneally disseminated tumor cells. The present study suggests a novel way to use alpha-GalCer in immunotherapy for peritoneally |
| Volume | 96(12) |
| Pages | 889-96 |
| Published | 2005-12-1 |
| DOI | 10.1111/j.1349-7006.2005.00123.x |
| PII | CAS |
| PMID | 16367909 |
| MeSH | Animals Antigens, Neoplasm / immunology Antineoplastic Agents / therapeutic use* Cell Communication Cell Line, Tumor Cell Survival Chemokine CCL21 Chemokines, CC / genetics* Dendritic Cells / drug effects Dendritic Cells / immunology* Dendritic Cells / physiology Galactosylceramides / therapeutic use* Genetic Engineering Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology Killer Cells, Natural / drug effects Killer Cells, Natural / immunology Lymphocyte Activation / drug effects Mice Mice, Inbred C57BL Mice, Inbred CBA Neoplasms / immunology* Neoplasms / pathology Ovalbumin / immunology Recombinant Proteins T-Lymphocytes / drug effects T-Lymphocytes / immunology |
| IF | 4.966 |
| Times Cited | 20 |
| WOS Category | ONCOLOGY |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 7 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | |